In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained ...

Chimeric antigen receptor T-cell therapy conferred sustained benefit to individuals with high-risk smoldering multiple myeloma, according to phase 2 trial results. All patients who received a single ...

Multiple myeloma is the second most common blood cancer in adults. It starts in the white blood cells that are responsible ...

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to ...

The medical community is now utilizing minimal residual disease (MRD) testing, which can detect a single cancer cell among a ...

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...

Immunotherapy is a type of cancer treatment that uses the power of a person’s immune system to fight their cancer. Instead of directly attacking cancer cells like chemotherapy or radiation, ...

Anemia often goes hand-in-hand with multiple myeloma. Sometimes, the cancer causes the anemia. And sometimes, the cancer treatment does. But it's possible to resolve it and feel better. (Photo Credit: ...

How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...